Mechanism of PARP inhibitor resistance and potential overcoming strategies

Xiaoyu Fu; Ping Li; Qi Zhou; Ruyuan He; Guannan Wang; Shiya Zhu; Amir Bagheri; Gary Kupfer; Huadong Pei; Juanjuan Li

Genes and Diseases (Jan 2024)

Mechanism of PARP inhibitor resistance and potential overcoming strategies

Xiaoyu Fu,
Ping Li,
Qi Zhou,
Ruyuan He,
Guannan Wang,
Shiya Zhu,
Amir Bagheri,
Gary Kupfer,
Huadong Pei,
Juanjuan Li

Affiliations

Xiaoyu Fu: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
Ping Li: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
Qi Zhou: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
Ruyuan He: Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
Guannan Wang: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
Shiya Zhu: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
Amir Bagheri: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
Gary Kupfer: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
Huadong Pei: Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Corresponding author.
Juanjuan Li: Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China; Corresponding author.

Journal volume & issue: Vol. 11, no. 1
pp. 306 – 320

Abstract

Read online

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous recombination (HR) repair deficiency, innate and acquired resistance to PARPi is a main challenge in the clinic. In this review, we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance, aiming at extending PARPi application and improving patient outcomes.

Published in Genes and Diseases

ISSN: 2352-3042 (Online)
Publisher: KeAi Communications Co., Ltd.
Country of publisher: China
LCC subjects: Medicine: Medicine (General); Science: Biology (General): Genetics
Website: https://www.keaipublishing.com/en/journals/genes-and-diseases/

About the journal

Abstract

Keywords